About US
Contact us
-
AbbVie nabs FDA's orphan drug tag for Humira in HSAbbVie ($ABBV) is working to lessen its reliance on blockbusterHumira, which is already facing biosimilar competition inIndia. But it's also working to broaden the drug's label, and on that front, it2015/5/18
-
Actavis talks to DOJ about resolving probe of Warner Chilcott marketing misdeedsActavis completed its buyout of Ireland'sWarner Chilcottmore than a year ago and is now trying to rid itself of some nasty legal entanglements that it picked up in the $8.5 billion deal. The drugmaker2015/5/18
-
Vertex eyes big revenue boost with FDA panel backing for OrkambiVertex Pharmaceuticals ($VRTX) wants to expand its cystic fibrosis market tenfold, and on Tuesday, it got one step closer. An FDA advisory committee voted 12 to 1 in favor of a new combo drug Orkambi,2015/5/14
-
Contrave controversy puts Orexigen, Takeda in unwelcome spotlightTheFDAwas none too happy with Orexigen ($OREX) when it put out some early positive cardio data for obesity drugContravein March. One reason? Early data can be misleading--and now, it looks like that m2015/5/14
-
Endo plots a double-sized salesforce, new DTC push for Stendra relaunchNot satisfied with the way its new purchase Auxilium had handled Stendra marketing, Endo ($ENDP) plans to relaunch the erectile dysfunction med, which it sells in partnership with Vivus ($VVUS). Endo2015/5/13
-
Baxter pads biopharma unit with pre-spinoff oncology buyAs Baxter ($BAX) gears up to spin off its biopharma unit into new companyBaxalta, it wants to make sure the new pharma has enough revenue to rely on. And to do that, it's bulking up. The Illinois com2015/5/13
-
When it comes to pharma corporate branding, Biogen is onto somethingPharma may have something to learn from Biogen's ($BIIB) recent move to lop the "Idec" off its name. It's not enough to rely on big drug brands and product messaging to attract consumers--and often, i2015/5/12
-
Teva passed up an opportunity to buy Mylan target Perrigo: GlobesSo far, Perrigo hasn't seemed too keen on selling itself to generics giant Mylan ($MYL). It's rejected the U.S. drugmaker three times. But word has it that Perrigo tried to link arms with another gene2015/5/12
-
FDA staffers raise doubts over key Vertex comboAs an FDA review nears for Vertex's ($VRTX) Kalydeco-lumacaftor tandem--approval of which could help Kalydeco reach 10 times the number ofcystic fibrosispatients it currently does--the agency's staffe2015/5/11
-
'No path forward' with Teva, Mylan pledges amid warring roadshowsLate last month, Teva ($TEVA) kicked off a roadshow to meet shareholders of its buyout target, Mylan ($MYL), and find out what price it'll need to put forth to convince them to support a deal. As Myla2015/5/11